Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

J.P. Morgan analyst James Gordon maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The ...

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well in a declining market. AstraZeneca stock is nearing a buy point after ...

The AstraZeneca PLC ADR AZN shed 1.22% to $72.60 Tuesday, on what proved to be an all-around mixed trading session for the ...

Astrazeneca (AZN) ended the recent trading session at $72.72, demonstrating a -0.45% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss ...

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.